The probability of the Bayer-MON deal closing hasn't changed appreciably in the past few months insofar as the key regulatory approvals, especially the EU and China, remain.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.